Injective price jumps as token buying pressure builds

Traders Union
All News
Crypto News
Injective surges 18.01% today to $7.06

Highlights

Binance US has enabled staking for Injective, significantly boosting trading volume and institutional interest in the token.
Native USDC integration into Injective expands liquidity for tokenized real-world assets and broadens stablecoin access for users.
INJ/USD maintains a strong bullish trend, but overbought conditions suggest consolidation between $6.04 support and $7.74 resistance in the near term.

Liquidity and trading interest rise as ecosystem upgrades drive demand

Binance US has introduced staking support for Injective, resulting in increased trading volume and heightened interest in the token. At the same time, native USDC has launched on the Injective network, providing users with direct access to Circle’s regulated stablecoin and opening new liquidity opportunities for tokenized real-world assets. These ecosystem upgrades are improving accessibility and expanding use cases for Injective.

Anton Kharitonov, expert at Traders Union, notes that INJ’s price has surged but now sits in extreme overbought territory. He highlights the positive impact of Binance US’s staking feature and the USDC integration, yet warns that momentum indicators such as RSI, Stochastic RSI, and CCI signal exhaustion. There is a risk of a swift correction if immediate support at $6.04 is breached. Kharitonov emphasizes that the technical setup does not justify further aggressive buying at this level. "Despite bullish news, I see elevated risk for late entrants, so caution is warranted here."

Viktoras Karapetjanc, expert at Traders Union, sees Injective’s structural outlook as strongly positive. He believes new staking options and direct USDC access are significant, fueling fresh demand and expanding real-world utility. Higher timeframes continue to support a bullish foundation, backed by sustained ecosystem progress. "With ecosystem upgrades and bullish structure intact, I expect further growth as market opportunities broaden for INJ."

Uptrend strength persists as overbought signals flag short-term risk

INJ/USD is trading firmly above its 20-day, 50-day, and 200-day moving averages, with the current price of $7.06 well above the MA-20 ($5.14), MA-50 ($4.14), and MA-200 ($4.24). This alignment signals a strong bullish trend across short-, medium-, and long-term timeframes, while the nearest major support is found at the Ichimoku Kijun level of $5.18 and resistance is now likely near the next round level or higher moving averages.

Momentum indicators show broad strength, with both the MACD and Average Directional Index (ADX) confirming bullish momentum on the daily interval. However, overbought signals are apparent from the Relative Strength Index (RSI) at 74.61, Stochastic RSI at 100, and Commodity Channel Index (CCI) at 213.54, suggesting short-term overextension. Bull/Bear Power (BBP) is positive at 1.30, indicating buyers dominate intraday, but its overbought reading aligns with the CCI and Stochastic RSI. The Awesome Oscillator (AO) also reinforces the bullish trend. The pair started the session with an upside gap of roughly $0.43, rising 18.01% and currently trades close to the day’s high. Intraday volatility stands at 10.74%. Overall, the intraday tone is strong toward the highs, and momentum signals generally confirm today’s rally, although overbought conditions warrant attention.

Earlier, analysts noted that Injective was exhibiting robust bullish momentum supported by technical trend strength. The latest developments, including new ecosystem upgrades and a surge in price action, further reinforce this positive trajectory, making a sustained move above $7.74 a pivotal signal for the next phase of upside potential.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.